Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for June 2009
June 1, 2009
- FDA and International Consortium Report New Data on Drug-Induced Liver Injury
- Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer
- Allos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting
- A.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical Oncology
- Antigenics Presents Positive Oncophage Interim Survival Data at ASCO
- Gemin X Announces Positive Results in Small Cell Lung Cancer from Phase 1b Trial of Obatoclax at Annual Meeting of the American Society of Clinical Oncology
- Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases
- ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO
- Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Activity in Patients with Hematologic Cancers
- In Clinical Trials VELCADE (Bortezomib) for Injection as a Foundation of Therapy Continues to Deliver Significant Response Rates in Previously Untreated Multiple Myeloma Patients
- ZymoGenetics Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar
- Synta Pharmaceuticals Announces Presentation of Preliminary Results of Phase 3 SYMMETRY Trial of Elesclomol in Metastatic Melanoma at ASCO 2009
- Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme
- Data Presented on Two Novel Millennium Investigational Oncology Drugs at ASCO
- Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO Annual Meeting
- Celldex Therapeutics Announces CDX-1307 Clinical Data at 45th Annual ASCO Meeting
- BioLineRx Announces Positive Preliminary Results From the Phase I/II Trial of BL-1040, the First Injectable Device Addressing Pathological Cardiac Remodeling
- Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
- ASCO Presentations Highlight Findings from Clinical Trials with ArQule's c-MET Inhibitor, ARQ 197
- Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Anti-PD-1 Antibody at American Society of Clinical Oncology Annual Meeting
- Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
- StemCells, Inc. to Present Phase I Clinical Trial Results at the 12th International Congress on NCL
- Alder Biopharmaceuticals Presents Results From Phase 1 Trial of ALD518 in Advanced Cancer at American Society of Clinical Oncology Annual Meeting
June 2, 2009
- Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
- Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
- Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting
- Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
- Imotuzumab Demonstrates Efficacy in Randomized Head & Neck Cancer Study Without the Toxicities Associated with Other EGFR Drugs
- Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT Phase 3 Clinical Program
- AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
- Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
- Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
- Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
- AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
- New Phase III NasalFent data reinforce superiority over the standard of care for breakthrough cancer pain
- Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
- Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
- Data from Enzo Therapeutics' Phase II Study of Crohn's Disease Presented at Prestigious Gastroenterology Conference
- GSK's Pazopanib Significantly Delays Tumor Progression in Patients with Advanced Kidney Cancer
- Argos Therapeutics Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the American Transplant Congress
- AEterna Zentaris Partner Keryx Reports Positive Phase 2 Data for Perifosine (KRX-0401) in Colon and Kidney Cancer at ASCO Meeting
- FDA Advisory Panel Recommends Approval of the Sedayst System
- Delcath Systems Granted Third Orphan Drug Designation
- Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR
- Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
- Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
- Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
- Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
- New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting
- Gloucester Pharmaceuticals Presents Positive Clinical Data for Romidepsin in CTCL and Further Preclinical Evidence of Synergism with Bortezomib at ASCO
- Pivotal Study Results: ChemGenex's Omacetaxine May Provide the First Viable Drug Treatment Option for Patients With a Highly Resistant Form of CML
- GTx's Toremifene 80 Mg Increased Bone Mineral Density in Multiple Clinically Relevant Subpopulations of Prostate Cancer Patients on Androgen Deprivation Therapy
- NeurogesX Receives FDA Orphan Drug Designation for Qutenza for Treatment of Postherpetic Neuralgia
- New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study
- Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
- Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
- Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
- Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
- Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients
- QLT Announces Positive Results from the Evaluation of Visudyne Combination Therapy
- Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
- PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN Presented in Oral Session at DDW 2009 Conference
June 3, 2009
- Data on VIVUS' Qnexa to be Presented During Two Podium Presentations at ADA Annual Meeting
- TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting
- New Data Suggest Treatment Regimens That Include ABRAXANE May Be Active in Treating Metastatic Melanoma
- CombinatoRx Announces Positive Results for Aligned-Release Synavive
- Positive Results from Pivotal Salix Phase III Study (Hepatic Encephalopathy) Presented at Meeting
- DAZMedia Opens LA Social Media Practice
- Access Pharmaceuticals Provides Update on ProLindac Phase 2 Ovarian Cancer Trial and Clinical Development Plan
- Advaxis Receives FDA Response to Orphan Drug Filing
- Generex Presents Positive Results of Phase 1 Prostate Cancer Vaccine Trial at the American Society of Clinical Oncology
- New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study Responses Observed at Lower Doses
- Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma
- Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma
- GPC Biotech AG (DE) - New Data from Satraplatin Phase 3 Trial in Second-Line Castrate-Refractory Prostate Cancer Presented at 2009 ASCO Annual Meeting
- FDA Forms Transparency Task Force
- New Findings Demonstrate Potential Benefits of GATTEX (teduglutide) in Phase 3 Study of Patients with Short Bowel Syndrome
- Newly Presented Data On Gaster Show Prevention Of Peptic Ulcers In Users Of Low-Dose Aspirin
- Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
- PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
- ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO's Prestigious Clinical Science Symposium
- Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
- Interim analysis confirms immunosafety of Rhucin
- Oxford BioMedica Presents Updated TroVax Phase I/II and II Results at ASCO Annual Meeting
- FDA MedWatch - Propylthiouracil (PTU) associated with risk of serious liver injury, including liver failure and death
- TNFerade Phase III Data Presented at ASCO
- Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
- Peregrine presents promising breast cancer data at ASCO
- Inovio Biomedical Influenza DNA Vaccines Demonstrate Potential to Protect Against Newly Emerging Flu Strains with Pandemic Potential
June 4, 2009
- EpiCept Releases New Data Demonstrating Long-Term Durability of Ceplene in Sustaining Leukemia-Free Survival
- Trabedersen shows good safety, tolerability and promising survival in patients with pancreatic carcinoma, malignant melanoma and colorectoral carcinoma
- EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study
- Positive Outcome Reached at 16 Weeks for Avexa's ATC Phase III Trial
- ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial
- Stiefel Laboratories Reaps First Fruits of Barrier Acquisition With Completion of Pivotal Phase III Clinical Trial for 200 mg Hyphanox(TM) (Itraconazole) Tablet
June 5, 2009
- Avandia Attorney Says Study Based on 'Useless Trick Science'
- Single Dose Palonosetron Prevents Emesis Induced By Chemotherapy In Non Hodgkin's Lymphoma Patients
- Tasigna shows rapid and deep responses in newly diagnosed patients with a form of chronic myeloid leukemia
- PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
- Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical Trial
- ACTEMRA (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress
- Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
- Paclitaxel Poliglumex (OPAXIO Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
- Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia
- Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
- Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
- GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
June 8, 2009
- Tranzyme Pharma to Present Multiple Applications of its Proprietary Drug Discovery Technology at the 21st American Peptide Society Symposium
- Alnylam and Cubist Report Preliminary Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
- GTx Announces Ostarine (MK-2866) Clinical Trial Data to be Presented at ENDO 2009
- Alnylam to Webcast Conference Call to Discuss Preliminary Data from Phase II Study of ALN-RSV01
- Study Shows Consistent Use of Insulin Pump Therapy, Augmented with Continuous Glucose Monitoring, Results in Significant A1C Reductions
- Update on Lu AA21004 Clinical Development Programme in Major Depressive Disorder
- Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
- Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
- ChemGenex's Omacetaxine Shows Activity in Refractory CML
- Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between October - December 2008
- ChemGenex's Omacetaxine Kills Leukemic Stem Cells in Human CML Models
- Impax Pharmaceuticals Announces Presentation of IPX066 Phase II Data at 13th International Congress of Parkinson's Disease and Movement Disorders
- Initial Therapy with JANUMET (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes
- Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma
- Dyax Presents Integrated Analysis of Phase 3 Data for DX-88 for Hereditary Angioedema
- Halozyme's Phase 2 Insulin-PH20 Study Demonstrates Faster Insulin Absorption and Superior Glucose Control in Type 1 Diabetic Patients
- Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isoform-Selective PI3 Kinase Inhibitor, Under Evaluation in Patients with Hematologic Malignancies
- Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines
June 9, 2009
- Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
- Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
- Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
- Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
- Orexigen Therapeutics Presents Additional NB-302 Contrave Data at American Diabetes Association (ADA) 69th Scientific Sessions
- Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
- Afinitor Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
- Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
- ConjuChem Reports Data on PC-DAC: Exendin-4 and PC-Insulin at 2009 American Diabetes Association Meeting
- AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
- Abbott's TRILIPIX (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
- Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
- Talecris Biotherapeutics Receives Orphan Drug Designation for Plasmin (Human) to Treat Acute Peripheral Arterial Occlusion
- Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
- Celator Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
- Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
- Clinical Pharmacology Study With AZILECT (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
- Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
- Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
- Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
- Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
- ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
- Kamada Reports Positive Proof-of-Concept Data for Inhaled Alpha-1 Antitrypsin in Bronchiectasis
- StemCells, Inc. Announces Positive Phase I Batten Trial Results
- VIAject Presentations at ADA Meeting Highlight Drug's Mechanism of Absorption and Microvascular Effects
- Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
- Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
- The Lancet publishes direct comparison study between liraglutide and exenatide
- MedThink Communications Wins Four Aster Awards in Healthcare Advertising Agency Competition
- Transcept Pharmaceuticals Presents Data at SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
- Weber Shandwick Chosen By National Marrow Donor Program To Head Awareness Campaign
- NicOx Publishes Results of the ZEST Phase 2 Study for Naproxcinod
- Arete Therapeutics Reports Preclinical and Clinical Data at ADA
- Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data
- Chandler Chicco Companies Announces New Brandtectonics Access US Offering
June 10, 2009
- Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis
- Response Rates of 58-74% With Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
- Orange Label Advertising Agency Recognized for its Healthcare Marketing and Branding Prowess
- Nutra Pharma Announces Study Showing RPI-78 More Effective than Morphine in the Treatment of Moderate to Severe Pain
- Avid Radiopharmaceuticals to Present Clinical Trial Advances in Molecular Imaging of Alzheimer's Disease, Parkinson's Disease and Diabetes
- Genmab Announces Partial Clinical Hold on Zalutumumab Studies
- InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
- Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride
- Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function
- Joint Statement on Atypical Antipsychotic Use in Children
- Cline Davis & Mann Launches Brand Anatomy, a New Branding Division Focused Exclusively on Healthcare Clients
- FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
- Presented at SLEEP 2009: New Controlled-Release Formulations of Proven Drug Being Developed for Middle-of-the-Night Awakening
- Juvista European Phase 2 clinical trial
- New Analyses Show Nasonex Is More Effective Than Loratadine For The Treatment Of Nasal Allergy Symptoms And At Least Comparable For Ocular Symptoms
- Chandler Chicco Companies launches Brandtectonics Access
- Data Demonstrate Aerius® (Desloratadine) Reduces Symptoms And Improves Quality Of Life In Patients With Persistent Allergic Rhinitis
- Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes
- New Analysis Shows Efficacy of Simponi (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
- Newly Analyzed Data Show Daily Treatment With Nasonex Significantly Reduces Symptom Recurrence In Patients With Perennial Allergic Rhinitis
- Two-Year Data Show Patients Receiving Simponi (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
June 11, 2009
- Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA (Formerly LymphoStat-B) in Patients With Active Systemic Lupus Erythematosus
- Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference
- Genetic Variant Associated With Resistance To Chemotherapy Drug In Women With Breast Cancer
- HRV phase IIa study achieves clinical proof-of-concept
- New Versartis Data Demonstrates Potential for Monthly Dosing
- Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594
- Human Genome Sciences Reports Positive Long-Term Data For Benlysta (Formerly Lymphostat-B) In Patients With Active Systemic Lupus Erythematosus
- Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
- GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting
- New Data on Once-Daily Extended Release Pramipexole Presented at 13th International Congress of Parkinson's Disease and Movement Disorders (MDS)
- Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
- Enobia Announces Positive Interim Clinical Results with ENB-0040
- Data Demonstrated ACTEMRA (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
- Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
- Cannabis Science: Can Cannabis-Based Drugs Slow the H1N1 "Swine Flu" Pandemic?
- Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin for Insomnia in Elderly Patients
- Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show
- New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
- MabThera reduces progression of joint damage in rheumatoid arthritis when used as a first-line biologic
June 12, 2009
- Orencia (Abatacept) Demonstrates Consistent Safety And Effectiveness Over 7 Years
- NicOx presents naproxcinod results in several posters at EULAR
- Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine
- NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
- CombinatoRx Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009
June 15, 2009
- Aegerion Pharmaceuticals Announces Interim Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile
- MedWatch - Sirolimus (marketed as Rapamune):clinical trial suggests increased mortality in stable liver transplant patients after conversion from CNI-based immunosuppressive regimen to sirolimus
- FDA Issues Public Health Advisory Regarding Levemir Insulin
- Advaxis' Clinical Trial Survival Data Significantly Exceeds the National Cancer Institute's Median Survival Statistic
- New Enbrel (etanercept) Data to be presented at EULAR
- Successful phase II/III trial of new therapy for adrenal insufficiency
June 16, 2009
- New Animal Study of Rexahn's Serdaxin Shows Drug's Promise to Treat Anxiety and Depression with Minimal Side Effects
- Obecure Achieves Successful Results in Its Proof of Concept Clinical Study Evaluating the Ability of Histalean to Mitigate Weight Gain Associated With Olanzapine
- New Study Shows Javelin Pharmaceutical's Dyloject Well-Tolerated in High-Risk Patients with Impaired Renal and Hepatic Function
- Actemra study shows patients experienced a significant inhibition in the progression of structural joint damage
- MedWatch - Stimulant Medication in Children with AD/HD - FDA Perspective on Study Data Published about Potential Risks of AD/HD Stimulant Medications
- Celgene Announces Positive Top Line Data from Randomized Controlled Phase II Study of Apremilast in Psoriatic Arthritis
- Wyeth Announces Holder Right to Surrender Convertible Debentures
- QuantRx Announces FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
- ARYx Therapeutics Inc. Updates Progress with Tecarfarin EmbraceAC Study
- Theratechnologies presents results at ENDO
- Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily Infergen with Ribavirin in Hepatitis C Virus Treatment Failures
- Two Newly-Published Scientific Papers Showed That the Steroid Used in Company's Iluvien Device Acted as Both a VEGF Inhibitor and Neuroprotectant
June 17, 2009
- Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data
- Compugen Transfers to The NASDAQ Capital Market
- Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
- Somnia Anesthesia: 3rd Study Confirms Anesthesia Improves Outcomes in Colonoscopies
- Pharming announces Euro 9 million debt reduction and continued equity financing with Ya Global
- Phase II trial demonstrates Elacytarabine may increase survival threefold in patients with late-stage leukaemia
- TransMolecular's 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue
- Spectrum Pharmaceuticals to Raise $10 Million from Institutional Investors at $5.83 Per Share, the Closing Bid Price on Friday, June 12, 2009
- Deltagen Reports 2009 First Quarter Financial Results
- The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
- Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
- S&P: Watson Pharmaceuticals Inc. $1.75 Billion Acquisition Of Arrow Pharmaceuticals Group Will Not Affect Ratings
- QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne combination therapy
- OcuCure Therapeutics? Topical Vascular Targeting Agent Demonstrates Long Term Safety
- Pulmo BioTech Inc. Announces Fund Raising Agreement with Moody Capital Solutions, Inc.
- Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
- Pitavastatin Demonstrates Promise for Low Incidence of Drug-Drug Interaction
- Pixantrone Overview in Non-Hodgkin's Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
- PCMA: President Obama, MedPAC Call for Follow-On Biologics
- NicOx: additional 24?hour blood pressure results for naproxcinod presented at the European Meeting on Hypertension
- New prostate cancer imaging agent shows promise in identifying metasatic lesions more quickly and accurately vs. current compounds
- New Study Benchmarks How Companies are Interpreting the New PhRMA Code
- Quest PharmaTech Announces First Quarter Results
June 18, 2009
- Alnylam and Collaborators Present New Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK9, a Genetically Validated Regulator of LDL Metabolism
- CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity in Animal Trial for Multiple Myeloma
- Cefepime (marketed as Maxipime) Update of Ongoing Safety Review
- Tianyin Pharmaceutical Co., Inc. Provides Fiscal 2010 Guidance
- Spectrum Pharmaceuticals Receives $10 Million from Two Institutional Investors at $5.83 Per Share
June 19, 2009
- Avir Green Hills: Excellent Preclinical Data on Novel Type of Intranasal H5N1 Influenza Vaccine ? Technology Also Suitable for Vaccination against Swine Flu
- Cell Therapeutics on Preliminary List of Additions to Russell 3000 Index and Russell Global Index
- ILSI Biomed: Venture Capitalists Concerned of New FDA Commissioner's Impact on Industry
- AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
- Enzo Biochem Announces Record 2009 Fiscal Third Quarter Revenues
- ADVENTRX Pharmaceuticals Announces Closing of Financing
- Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia
- Immunomedics Reports Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma
- Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
- Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study for Treatment of Acne With Enhanced Microcyn Hydrogel Formulation
- EpiCept Announces Pricing of Public Offering
- AEterna Zentaris to Raise US$10 Million from Institutional Investors at US$1.88 Per Share
- Impax Laboratories to be Added to Russell 3000® Index and NASDAQ Biotechnology Equal Weighted Index
June 22, 2009
- ImmunoGen, Inc. Prices Public Offering of Common Stock
- KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K
- MedWatch - Cefepime: FDA determined that data review do not indicate a higher rate of death in cefepime-treated patients
- FDA Issues Safety Communication about an Ongoing Review of Stimulant Medications Used in Children with ADHD
- Forest Laboratories Announces Positive Top-line Data from Two Pivotal Phase III Trials of Ceftaroline for the Treatment of Community-acquired Bacterial Pneumonia (CABP) Requiring Hospitalization
- Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
- Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx Gentamicin Topical for the Treatment and Prevention of Diabetic Foot Infections
- Merrion Pharmaceuticals Announces Positive Phase IIB Study For Orazol Tablet Form of Zoledronate IV Infusion At ASCO Annual Meeting
- Fitch: H1N1 (Swine Flu) - A Reminder That Trade Bans Negatively Affect Cash Flow & Credit Profiles
June 23, 2009
- Oral Rivaroxaban Reduces Death/Stroke/Further Heart Attack For Patients After Heart Attack Or Unstable Angina
- The Alliance for the Advancement of Adult Stem Cell Therapy and Research Announces Successful Treatment of End-Stage Heart Disease with Stem Cells
- Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Inflammatory Bowel Disease
- Brain cancer drug update confirms exquisite targeting & promising efficacy
- New research highlights potential of novel alpha-pharmaceutical in targeting and killing breast cancer cells
- Phase II trial demonstrates Elacytarabine may increase survival threefold in patients with late-stage leukaemia
- Acucela's Novel Visual Cycle Modulator Demonstrates Promise as a Treatment for Dry Age-Related Macular Degeneration
June 24, 2009
- Pro-Pharmaceuticals' Chief Scientist Published Articles in Three Prestigious Peer-Reviewed Journals
- BioLineRx Announces New Results Confirming the Mode of Action of Its Anti-Psychotic Drug- BL-1020
- Osiris Therapeutics Reports Interim Data for COPD Stem Cell Study
- Eclipsys Corporation and DrFirst Physician Honored with ?E-Prescriber of the Year? Award at the 4th Annual Surescripts Safe-Rx Ceremony
- CTIA- The Wireless Association Forum: Medical and Policy Experts Agree Wireless Technology Makes Healthcare More Efficient, Effective and Patient-Focused
- Spherix Announces Positive Phase 2 Study Results
June 25, 2009
- Mayo Clinic Researchers Highlight Prostate Cancer Study with Ipilimumab
- Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
- New Data from CLARITY Study Presented at 19th ENS Meeting Show Rapid and Sustained MS Relapse Reduction for Cladribine Tablets
- CytRx to Present Statistically Significant Evidence of Arimoclomol's Ability to Protect Experimental Animals from the Effects of Hypoxia at the 2009 International Society on Oxygen Transport to Tissue Conference
- Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study
- FDA Approves Generic Prescription-Only Version of Plan B Emergency Contraceptive for Women Ages 17 and Under
- Afinitor and Sandostatin LAR Phase II Data Show Advanced Pancreatic NET Patients Remain Progression-Free for Nearly 17 Months
- Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
- The Biomarkers Consortium Completes First Project to Show that Adiponectin is a Predictive Biomarker for Type 2 Diabetes
June 26, 2009
June 28, 2009
- Supportive Care In Cancer: Second Generation 5-Ht3 Antagonists Open New Perspectives In Emesis Prevention
- Second U.S. Independent Laboratory Confirms that Oculus Innovative Sciences' Microcyn Technology Effective at Inactivating H1N1 Swine Flu
- Generex's New Vaccine Technology Could Speed Flu Vaccine Availability
- Published Study Shows Novel Compounds May Help Protect Against Respiratory Depression
- iCo Therapeutics Positive Oral Amphotericin B Data Published in the Journal of Infectious Diseases
- Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
- Drug May Prolong Survival in Melanoma Patients
- Crucell Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines
- Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
- Advanced Life Sciences' Restanza Shows 100% Survival In Confirmatory Anthrax Study
June 29, 2009
- CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-line Treatment for Acute Promyelocytic Leukemia
- BioSante Pharmaceuticals Comments on Study Showing No Increased Risk of Breast Cancer in Women Using Testosterone for Low Libido
- AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
June 30, 2009
- XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
- Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
- DuoCort: New chronotherapy for adrenal insufficiency
- Inovio assesses vaccine against swine flu
- Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
- Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
- Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
- iMedicor Adds Pre-populated CV's to its HIPAA Compliant Portal Through Partnership with VitalsSM
- MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
- New Data: Efficacy and Responder Analyses of Divigel (estradiol gel) 0.1 percent for the Treatment of Menopause
- Santhera's FJORD Phase IIb Study Demonstrates Efficacy of JP-1730/Fipamezole for the Treatment of Dyskinesia in Parkinson's Disease
- New Data Supports Significant Economic and Clinical Value of Menopur in IVF
